A simple blood test may soon change how Alzheimer’s disease is diagnosed. In a new clinical study involving 200 adults with cognitive symptoms, researchers found that measuring the biomarker p-tau217 significantly improved diagnostic accuracy. Standard clinical evaluations correctly identified Alzheimer’s in about 75% of cases, but when doctors incorporated the blood test results, accuracy rose to 94.5%.
P-tau217 is a phosphorylated form of tau protein linked to the brain changes seen in Alzheimer’s. Elevated levels in the blood have emerged as one of the strongest early indicators of the disease. Unlike costly brain scans or invasive spinal taps, the blood test offers a more accessible option that can be used in routine neurology clinics. In roughly one in four cases, test results led physicians to change their initial diagnosis. Doctors also reported greater confidence in their conclusions after reviewing biomarker data.
The findings suggest that blood-based biomarkers could move Alzheimer’s detection earlier and make diagnosis less burdensome for patients. As populations age and dementia rates climb, scalable, non-invasive tools may play a critical role in identifying cognitive decline before symptoms advance. While further validation is needed, this approach could mark a significant shift toward more precise and timely care.
SOURCE:
MedicalXpress, February 22, 2026